Next Article in Journal
The Case of an Endometrial Cancer Patient with Breast Cancer Who Has Achieved Long-Term Survival via Letrozole Monotherapy
Next Article in Special Issue
Role of Some microRNA/ADAM Proteins Axes in Gastrointestinal Cancers as a Novel Biomarkers and Potential Therapeutic Targets—A Review
Previous Article in Journal
A Pilot Study of a Panel of Ocular Inflammation Biomarkers in Patients with Primary Sjögren’s Syndrome
Previous Article in Special Issue
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
 
 

Order Article Reprints

Journal: Curr. Issues Mol. Biol., 2023
Volume: 45
Number: 189

Article: Infliximab Inhibits Colitis Associated Cancer in Model Mice by Downregulating Genes Associated with Mast Cells and Decreasing Their Accumulation
Authors: by Dan-Yang Wang, Shinobu Ohnuma, Hideyuki Suzuki, Masaharu Ishida, Kentaro Ishii, Takashi Hirosawa, Tomoaki Hirashima, Megumi Murakami, Minoru Kobayashi, Katsuyoshi Kudoh, Sho Haneda, Hiroaki Musha, Takeshi Naitoh and Michiaki Unno
Link: https://www.mdpi.com/1467-3045/45/4/189

MDPI provides article reprints in high quality with convenient shipping to destinations worldwide. The articles are printed in on premium paper with high-resolution figures. Our covers are customized to your article and designed to be complimentary to the journal. These reprints are ideal additions to your portfolio. Copy details: 135g/m2 paper, 2x stitched, full colour and glossy finish, orderable in quantities from 10 to 1000.

If you have any questions, or special requests, please write to our support team; we are happy to provide you with the information you need.

Reprint Options

If you need more than 400 copies, please contact us by e-mail (publisher@mdpi.com) and we will prepare an individual offer for you.

Order Cost and Details

Contact Person

Invoice Address

Notes or Comments

Validate and Place Order

The order must be prepaid after it is placed

req denotes required fields.
Back to TopTop